tbuckley/cabot-search huggingface dataset:
Biochemical and Serological Markers of Liver Function in Liver Transplant Recipients with Primary Biliary Cholangitis
Authors: J. Raczynska, L. Paczek, A. Habior, B. Foroncewicz, M. Zielenkiewicz, A. Bauer, T. Cieciura, M. Krajewska, M. Florczak, M. Mulka, K. Mucha
Journal: Journal of Hepatology (2016)
Screening for Liver Disease in the General Population: The Potential Utility of Using AST/ALT Ratio
Authors: S. Carvalhana, J. Leitão, A.C. Alves, A.P. Silva, F. Velasco, I. Medeiros, A. Carvalho, M. Bourbon, H. Cortez-Pinto
Journal: Journal of Hepatology (2016)
Long-term follow-up confirms a survival advantage of paclitaxel-cisplatin (CP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer
Authors: M Piccart, K Bertelsen, G Stuart, J Cassidy, Ignace Vergote, E Simonsen, K Swenerton, S Kaye, J Roy, B Baron
Journal: Annals of Oncology (2002)
Screening For Anti-Leukemic CTLs After Allogeneic Hematopoietic Stem Cell Transplantation Applying Streptamer Technology
Authors: Falk Heidenreich, Elke Rücker-Braun, Sebastian Tuve, Marc Schmitz, Rebekka Wehner, Antje Tunger, Marcus Odendahl, Tonn Torsten, Martin Bornhäuser, Johannes Schetelig, Cornelia S. Link
Journal: Blood (2013)
Combined analysis of the EORTC and SWOG phase II trials of imatinib in advanced dermatofibrosarcoma protuberans (DFSP)
Authors: SM Schuetze, P Rutkowski, MM Van Glabbeke, C Rankin, BP Rubin, AJ Lazar, Maria Debiec-Rychter, H Gelderblom, P Hohenberger, AT van Oosterom
Journal: Journal of Clinical Oncology (2009)
Studying the gene expression profile among circulating tumor cells.
Authors: Ioannis Papasotiriou, Dimitrios Ntanovasilis, Panagiotis Apostolou
Journal: Journal of Clinical Oncology (2016)

e23099 Background: Circulating tumor cells (CTCs) are cells that have detached from the primary tumor and flow into the blood or lymphatic circulation creating a metastasis. Despite their rare kind of cancer cells in the blood, CTCs are widely used as a predictive marker for cancer progression. The last years there have been made great efforts in isolating and characterizing the above cell population. However, it is not clear understood the mechanism by which CTCs contribute to metastasis and response to treatment. The present study aimed to identify the gene expression profile of CTCs in different cancer types. Methods: Blood samples were collected from 20 patients suffered from breast, colorectal, lung and prostate cancer, in different stages of the disease. CTCs were isolated from the above samples using enrichment isolation protocol. RNA was extracted and used as template for DNA microarray experiments, using the the Human MI ReadyArray platform. A commercial RNA, representing different human tissues, was used as reference sample. The microarray data were normalized using background subscription and analysis of variance was used. Genes with log2ratios of means > 2 were selected for further analysis. Results: In breast cancer more than 160 genes were over-expressed in all samples. The number was equal in prostate CTCs and lower on the other two types. The clustering analysis revealed that there was no gene which was over-expressed in all cases. The clustering analysis in pairs revealed that in all groups there were observed genes correlated with signal transduction pathways (NDRG2, ATF7, TAOK2, RNF24) and cytoskeleton (ACE, KLHL33). When the clustered group contained three types of cancer, the number of genes was quite lower; however, genes correlated with signaling were over-expressed. In clustering analysis of all samples, no gene was observed with log2ratio > 2. Conclusions: The present study demonstrated that CTCs from different cancer types have a different gene expression pattern. Furthermore, the identification of specific genes expressed in all samples, might contribute to new drug-able targets discovery.Further studies, in more samples, are needed to confirm all the above, so that it can be validate them in order to be used at clinical level.
Gap Junction Opener Improves Endothelial Dysfunction and Decreases Hepatic Vascular Resistance in Cirrhotic Rats
Authors: M. Hernandez-Guerra, D. Morales-Arraez, J. Gonzalez-Paredes, K. Haugan, G. Hernandez-Mesa, R. De La Barreda, B. Abrante, B. Larsen, E. Quintero
Journal: Journal of Hepatology (2016)
Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection
Authors: M.G. Berg, D. Lee, K. Coller, M. Frankel, A. Aronsohn, K. Cheng, K. Forberg, M. Marcinkus, S. Naccache, G. Dawson, C. Brennan, D. Jensen, J. Hackett, C. Chiu
Journal: Journal of Hepatology (2016)
Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia.
Authors: Brian V Balgobind, Marry M van den Heuvel-Eibrink, Renee X Menezes, Dirk Reinhardt, Iris H.I.M. Hollink, Susan T.J.C.M. Arentsen-Peters, Elisabeth R van Wering, Gertjan Kaspers, Jaqueline Cloos, Eveline S.J.M de Bont, Andre Baruchel, Jean-Michel Cayuela, Jan Stary, Jan Trka, Berna Beverloo, Rob Pieters, Christian M Zwaan, Monique L. Den Boer
Journal: Blood (2008)
PET-BASED RADIOTHERAPY PLANNING IS HIGHLY COST-EFFECTIVE COMPARED TO CT-BASED PLANNING: A MODEL-BASED EVALUATION
Authors: Mathilda L Bongers, Veerle M. H Coupe, Dirk De Ruysscher, Cary Oberije, Philippe Lambin, Carin A Uyl-De Groot
Journal: Journal of Thoracic Oncology (2013)
Exercise Therapy in Patients Consuming Moderate Alcohol: A Randomised Control Trial
Authors: D. Houghton, K. Hallsworth, C. Thoma, S. Cassidy, T. Hardy, K. Hollingsworth, R. Taylor, C. Day, S. Masson, S. McPherson, Q. Anstee, M. Trenell
Journal: Journal of Hepatology (2016)
A High Density of Mutations within HLA Class I and II HBsAg/RT Epitopes Characterizes HBV Variants Emerging during Immune-Suppression Driven HBV Reactivation
Authors: R. Salpini, A. Grifoni, A. Lo Presti, A. Minutolo, A. Battisti, L. Colagrossi, M. Amicosante, V. Colizzi, A. Marrone, N. Coppola, L. Sarmati, M. Andreoni, M. Angelico, M. Ciccozzi, C.F. Perno, C. Montesano, V. Svicher
Journal: Journal of Hepatology (2016)
Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).
Authors: Mohamad Mohty, Xavier Cahu, Catherine Faucher, Patrice Chevallier, Norbert Vey, Jean El-Cheikh, Thierry Guillaume, Sabine Furst, Jacques Delaunay, Hugues de Lavallade, Philippe Moreau, Jean-Albert Gastaut, Jean-Luc Harousseau, Didier Blaise
Journal: Blood (2007)
Salvage treatment of relapsed/refractory small cell lung cancer with pazopanib: A Hellenic Oncology Research Group’s (HORG) phase II study.
Authors: Athanasios Kotsakis, Vasilis Karavasilis, Sofia Agelaki, Nikolaos K. Kentepozidis, Stavros Peroukidis, Epaminontas Samantas, Charalampos Christofyllakis, Eleftheria- Kleio Dermitzaki, Filippos Koinis, E Hartabilas, George Fountzilas, Efthimios Prinarakis, Vassilis Georgoulias
Journal: Journal of Clinical Oncology (2016)

8561 Background: Pazopanib (PZB) is a small anti-angiogenic molecule inhibiting the tyrosine kinase of VEGFR-1, VEGFR-2, VEGFR-3, PDGF, and c-kit. Several studies have shown that angiogenesis is of paramount importance in the development of SCLC. A multicenter phase II study of 2nd line PZB in pts with relapsed SCLC was conducted. Methods: This was a 2-cohort, non-randomized with a two-stage design phase II study. Pts with histologically confirmed SCLC, PS 0-1, sensitive (cohort A: relapse > 90 days from the 1stline treatment) and resistant/refractory (cohort B: relapse < 90 days) and measurable disease were enrolled. Treatment consisted of p.o. PZB 800 mg/d, q28 days, until disease progression. The primary endpoint was progression-free rate (PFR) at 8 weeks (pre-planned sample size: 39 eligible pts/cohort). Results: 58 pts (39 and 19 pts in cohorts A and B, respectively) were enrolled. Recruitment in Cohort B was terminated due to lack of efficacy as per protocol. Median age was 64.5 years (range 39-82); male: n = 50 pts; PS 0-1: n = 55 pts. After a central review, In Cohort B, one pt experienced PR and 4 SD with an overall PFR of 26.3% (95% CI, 6.5 - 46.1%); in cohort A, seven pts (17.9%) achieved PR and 16 (41.02%) SD for a PFR of 59% (95% CI, 43.5 - 74.4%). The median PFS in cohort A and B was 3.7 months (range 0.1 – 23) and 2 months (range 0.3 – 6), respectively. The median OS and 1-year survival rates were 10.6 months (0.1 – 38.4) and 38% (cohort A) and 4 months (0.5 - 15.7) and 10.5% (cohort B). Grade 4 adverse events (AEs) included neutropenia (n = 1 pt) and diarrhea (n = 1 pt) whereas grade 3 AEs were fatigue (n = 4 pts), nausea (n = 1 pt), diarrhea (n = 2 pts), hypertension (n = 1 pt) and transaminasaemia (n = 4 pts). There were no treatment-related deaths. Conclusions: PZB is an active and well-tolerated drug, particularly in patients with sensitive SCLC. Further investigation of PZB as monotherapy or combined with other agents in SCLC is warranted. Clinical trial information: NCT01713296.
Enhancing patient-health care provider (HCP) communication in oncology care in the United States.
Authors: Suzanne Lane, Shelagh Szabo, Ron Halbert, Hans-Peter Goertz, Catherine Lai, Aparna Parikh, Mikele Bunce, Raya Khoury, Art Small, Anthony Masaquel
Journal: Journal of Clinical Oncology (2016)

99 Background: Patient engagement is essential for high-quality care. This study aimed to develop novel communication tools to be used between patients and HCPs to address current gaps in cancer care. Methods: Qualitative interviews were conducted with 16 US patients with various cancers and stage, 6 oncology nurses, and 4 oncologists. Goals were to understand: patients’ changing concerns at diagnosis and during treatment; HCPs views on eliciting patient preferences; and perspectives from both on improving care. A thematic analysis was conducted to identify gaps in care. 8 patients rated their experience and importance of quality care items on a scale of 1 (not experienced/not important) to 5 (experienced/very important). Two draft tools were developed to address identified gaps. Results: None of the 16 patients reported using a communication tool before or during treatment. Gaps in quality care were identified, including communication, patient-centered care, education, and comprehensive care. Communication and patient-centered care items important to patients, but not always experienced, included clearly explained treatment options, time to discuss topics of concern, patient-led decision making, an open-minded care team, and the ability to change one’s mind (mean experience ≤ 4). The first tool assesses patient’s life and treatment goals and establishes early expectations through an open-ended questionnaire. This tool aims to enrich communication between patients and HCPs, enabling more patient-centered care. The second tool addresses the importance of ongoing education using a checklist. Treatment outcomes and the impact of treatment on QOL were identified as the two most important education items for patients when making treatment decisions (mean importance = 5). This tool aims to enhance educational discussions and enable patients to specify where more information is desired. Conclusions: Patients reported a need for communication tools at the beginning of treatment, specifically related to patient goals and educational needs. With patient and HCP input, two novel communication tools were developed to improve quality care. Future studies will validate and implement the tools in clinical practice.
Medical literature has seen a positive evolution of transparency
Authors: Al Weigel
Journal: BMJ (2016)

We read with interest Matheson’s article on “ghostwriting.”1 The International Society for Medical Publication Professionals (ISMPP), a not-for-profit professional society with over 1500 members involved in the publication of medical research, has carefully considered the article and has serious concerns with the author’s assertion of a “rebranding of ghostwriting.” Rather, we see a positive evolution of transparency and completeness in medical publications reporting industry research.

ISMPP’s longstanding position is …
A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs)
Authors: O. Rixe, C. Verslype, D. Khayat, S. Tejpar, B. Billemont, M. Crabbé, J. B. Méric, S. Assadourian, E. Van Cutsem
Journal: Journal of Clinical Oncology (2008)

3557 Background: Aflibercept (AF), a recombinant fusion molecule of the human VEGF receptor extracellular domains and the Fc portion of human IgG1, is a potent inhibitor of vascular endothelial growth factor. This study assessed the safety, dose limiting toxicities (DLTs)/recommended dose (RD) and PK of AF+I-LV5FU2. Methods: DE of AF followed by I-LV5FU2 (fixed standard dose) every 2 weeks (q2w) were explored. Results: 38 pts were enrolled (M/F: 18/20, median age 53 [19–77], ECOG PS 0/1: 24/13) including colorectal (23) and ovarian (5) cancers. Thirty six pts received prior chemotherapy (CT): median 3 [1–5]. A total of 404 cycles (median 10 [1–26]) of AF+I- LV5FU2 were administered across 4 AF dose levels (DL) ranging from 2.0 to 6.0 mg/kg. DLTs were: 2/12 pts at 4.0 (Grade (Gr) 3 proteinuria (PrU)>2wks including 1 pt with thrombotic microangiopathy), 2/10 pts at 5.0 (Gr 3 stomatitis and esophageal reflux) and 2/12 pts at 6.0 mg/kg (febrile neutropenia, Gr 3 stomatitis). The main AF-related Gr3–4 toxicities (% pts) were hypertension (32%) and PrU (11%). Moderate (Gr2) epistaxis (18%) and dysphonia (24%) were observed. Free and bound AF concentrations in combination with I-LV5FU2 are comparable to those observed with AF in monotherapy. AF had no influence on the PK of I-LV5FU2. Seven partial responses (synovial sarcoma, ovarian, pancreas and 4 colon cancers), 19 stable diseases were reported. AF 4.0 mg/kg was selected as the RD for feasibility based on PK analysis (excess of free AF at the end of the q2w dosing interval) and the absence of relationship between DE and clinical parameters (toxicity and activity). Conclusions: AF was safely combined with I-LV5FU2 with no evidence of exacerbation of CT-related toxicities. Class-effect toxicities related to AF were reported. Clear signs of activity were observed. Updated results will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration sanofi-aventis
Serum Levels of Lectin Complement Pathway Molecules do not Predominantly Determine the Risk of Bacterial Infections in Patients with Cirrhosis
Authors: I. Foldi, D. Tornai, T. Tornai, Z. Vitalis, I. Tornai, T. Dinya, P. Antal-Szalmas, M. Papp
Journal: Journal of Hepatology (2016)
Liver Stiffness Measured by Acoustic Radiation Force Impulse Quantification in Primary Sclerosing Cholangitis: A Comparison with Transient Elastography Performed by Fibroscan® and Other Non-Invasive Tests
Authors: D. Roccarina, F. Saffioti, M. Rosselli, M. Pinzani, A. Marshall, D. Thorburn
Journal: Journal of Hepatology (2016)
The Discrepancy between Transcriptome and Phenotype of Non-Alcoholic Fatty Liver Disease: Could its Phenotype Cross Over to that of Autoimmune Hepatitis?
Authors: A. Komori, K. Nagata, Y. Kugiyama, S. Bekki, S. Uchida, S. Hashimoto, A. Saeki, S. Nagaoka, K. Yamasaki, S. Abiru, H. Yatsuhashi
Journal: Journal of Hepatology (2016)
Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer.
Authors: Eric Jeffrey Sherman, Alan Loh Ho, Matthew G. Fury, Shrujal S. Baxi, Sofia Haque, Brynna Lane Lipson, Sarah Kurz, James A. Fagin, David G. Pfister
Journal: Journal of Clinical Oncology (2013)

6024 Background: Everolimus is an oral inhibitor of the mammalian target of rapamycin (mTOR). Unpublished work from the Fagin lab shows that mTORC1 is also required for the growth promoting effects of the oncoproteins RET/PTC, RAS and BRAF in rat thyroid PCCL3 cells. Further work shows synergy of mTORC inhibitors with RET kinase inhibitors in medullary thyroid cancer cell lines. Sorafenib is an oral kinase inhibitor with in vitro activity against multiple targets, including RAF, RET, VEGFR1, and VEGFR2 that is compendium approved for the treatment of radioactive iodine-refractory (RAIR) and medullary (MTC) thyroid cancer. Methods: The study was a single institution, two-stage phase II design. Primary objective was response rate initiated on 9/21/2010. Eligible patients (pts) had progressive, RAIR/fluorodeoxyglucose (18-F)-avid, recurrent/metastatic, non-anaplastic, thyroid cancer; RECIST measurable disease; and adequate organ/marrow function. Sorafenib was given at 400 mg orally twice a day and Everolimus at 5 mg orally once daily. 41 patients were enrolled; 36 were eligible for the primary endpoint of response and 3 were evaluable for toxicity only at the data cutoff date of 1/10/13. Seventeen patients are still actively on study. Mutational analyses of tissue is ongoing. Results: Of the 41 eligible pts, demographics: female- 44% (18); median age-61 years (35-79). Grade 4-5 adverse events at least possibly related to drug: grade 4- Alanine Aminotransferase Increase (1 pt): grade 4- Hyperglycemia (1 pt): grade 4-Pancreatitis (1 pt). Histology and response data by partial response, confirmed and unconfirmed, (PR), stable disease (SD) and progression of disease (POD) are in the table below. The median time on treatment is 167 days (range 1 to 797 days) at the cutoff date of 1/10/2013. Conclusions: The combination of sorafenib and everolimus shows promising results, especially in the Hurthle cell and medullary subgroups where data from studies at Ohio State have suggested very poor response to sorafenib alone. Clinical trial information: NCT01141309. [Table: see text]
Economic Evaluation of a Community Based Diagnostic Pathway to Screen Adults for Non-Alcoholic Fatty Liver Disease
Authors: L. Tanajewski, R. Harris, D.J. Harman, G.P. Aithal, T.R. Card, G. Gkountouras, V. Berdunov, I.N. Guha, R.A. Elliott
Journal: Journal of Hepatology (2016)
The dendritic cell–T helper 17–macrophage axis controls cholangiocyte injury and disease progression in murine and human biliary atresia
Authors: Celine S. Lages, Julia Simmons, Avery Maddox, Keaton Jones, Rebekah Karns, Rachel Sheridan, Shiva Kumar Shanmukhappa, Sujit Mohanty, Matthew Kofron, Pierre Russo, Yui‐Hsi Wang, Claire Chougnet, Alexander G. Miethke
Journal: Hepatology (2016)

Biliary atresia (BA) is a fibroinflammatory obstruction of the extrahepatic biliary tree in neonates. While intrahepatic bile duct proliferation is universal at diagnosis, bile duct paucity develops later. We hypothesized that polarized T helper lymphocyte responses orchestrate progression of intrahepatic biliary injury in this disease. Interleukin 17A (IL-17A)-green fluorescent protein, cluster of differentiation 11c (CD11c)/diphtheria toxin receptor, and IL-17 receptor A−/− mice were used to examine T-lymphocyte polarization, inflammatory leukocyte recruitment, and biliary injury in rhesus rotavirus–induced BA. Multiparameter flow cytometry and automated image analysis of immunostaining were applied to liver tissue samples from infants with BA. In the mouse model, activated CD4+ lymphocytes started to emerge in the liver on day 8 after viral challenge, while innate immune responses were waning. Plasma IL-17A levels rose concomitantly with hepatic accumulation of T helper 17 lymphocytes and myeloid dendritic cells. Targeted depletion of CD11c+ dendritic cells diminished hepatic IL-17A production and ameliorated intrahepatic bile duct injury. Recombinant IL-17A induced expression of chemokine (C-C motif) ligand 2 in neonatal cholangiocytes in vitro, and blockade of the corresponding chemokine (C-C motif) receptor 2 reduced recruitment of inflammatory macrophages to the liver in vivo. Genetic disruption of IL-17A signaling was associated with down-regulation of hepatic Ccl2/Ccr2 messenger RNA expression, reduced infiltration of the liver with inflammatory Ly6Chi macrophages, and improved survival. In the liver of infants with BA, cholangiocytes were found to express IL-17 receptor A, and the prevalence of IL-17A+ cells was positively correlated with the degree of CD68+ macrophage infiltration at diagnosis. Hepatic CD4+ lymphocytes were chief producers of IL-17A in patients with progressive disease undergoing liver transplantation. Conclusion: These findings identify the dendritic cell–T helper 17–macrophage axis as a target for the development of strategies to block progression of intrahepatic bile duct injury in patients with BA. (Hepatology 2017;65:174-188).
Long-term follow-up of the PI3Kδ inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.
Authors: Howard A. Burris, Ian Flinn, Matthew Alexander Lunning, Julie Vose, Nathan Hale Fowler, Loretta J. Nastoupil, Susan Mary O'Brien, Marshall T. Schreeder, Manish R. Patel, Timothy Fenske, Danielle M. Brander, Tanya Siddiqi, Christopher Flowers, Jan Andreas Burger, William G. Wierda, John G. Kuhn, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Owen A. O'Connor
Journal: Journal of Clinical Oncology (2016)

7512 Background: TGR-1202 is a novel, once-daily PI3Kδ inhibitor with a differentiated safety profile from other PI3Kδ inhibitors, and demonstrated activity in patients (pts) with advanced hematologic malignancies. An integrated-analysis is presented of pts dosed with TGR-1202 monotherapy or combined with the glycoengineered CD20 mAb ublituximab (UTX). Methods: There were no limits on prior therapies (Tx). TGR-1202 was escalated in 3 + 3 design with expansion cohorts explored. The primary endpoint was safety and efficacy was a secondary endpoint. Results: A total of 152 pts (81 monotherapy/71 combined with UTX), including 41 Follicular (FL), 40 CLL/SLL, 38 DLBCL, 11 Marginal Zone (MZL), 9 Hodgkins (HL), 8 Mantle Cell (MCL) and 5 other, were exposed to at least one dose of TGR-1202. Median age 65 yrs (22-86); 100 M/52 F; median # prior Tx = 3 (1-14); 53% refractory to immediate prior Tx. Most frequent reported AE's (all grades; Gr 3/4): nausea (44%; 1%), diarrhea (42%; 2%), fatigue (36%; 3%), vomiting (23%; 0%) and neutropenia (19%; 16%). AST/ALT increase was 6% (3% Gr 3/4), pneumonia 6% (5% Gr 3/4) and pneumonitis 1% (<1% Gr 3/4). 64 pts received TGR-1202 for 6+ mos, 33 for 1+ year, with longest on 30+ mos. Discontinuations due to AE's occurred in 8% of pts. 109 pts received the therapeutic targeted dose and were evaluable for efficacy. Median PFS for TGR-1202 monotherapy was 24 mos and 27 mos in CLL and iNHL, respectively. Median PFS for TGR-1202 + UTX has not been reached for either CLL or iNHL. Majority of DLBCL responses occurred with TGR-1202 + UTX, including 3 CR's and majority were of GCB subtype. Conclusions: TGR-1202 has exhibited a markedly differentiated safety profile from other PI3Kδ inhibitors to date with few discontinuations due to AE's and limited G 3/4 events. Robust activity was observed in CLL and iNHL. Phase 2 and 3 trials are ongoing both alone and in combo with UTX in CLL, DLBCL, and iNHL. Clinical trial information: NCT01767766. Clinical trial information: NCT02006485.Disease Pts n CR n (%) PR n (%) ORR n (%) CLL/SLL 27 1 (4) 23* (85) 24 (89) iNHL (FL, MZL) 37 4 (11) 14 (38) 18 (49) aNHL (DLBCL, MCL, Richters) 37 3 (8) 6 (16) 9 (24) HL 8 - 1 (13) 1 (13) * 6/23 with persistent lymphocytosis; all on monotherapy.
Osteopontin: A Key Regulator of Liver Metabolism during Regeneration after Partial Hepatectomy
Authors: M. Nuñez-García, B. Gomez-Santos, X. Buqué, J.L. García-Rodriguez, M.R. Romero, J.J.G. Marín, B. Arteta, C. García-Monzón, W. Syn, O. Fresnedo, P. Aspichueta
Journal: Journal of Hepatology (2016)